Clinical Trials Logo

Filter by:
NCT ID: NCT00622882 Recruiting - Clinical trials for Staphylococcus Aureus Bacteremia

Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia

Start date: October 2007
Phase: N/A
Study type: Interventional

The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB). This study will also determine if such consultations could reduce the duration of hospitalisation, recurrence and financial costs in patients with this infection.

NCT ID: NCT00611026 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

NCT ID: NCT00607685 Completed - Glaucoma Clinical Trials

5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy

Start date: February 2008
Phase: Phase 4
Study type: Interventional

Trabeculectomy is the most effective method of lowering intraocular pressure in glaucoma that is not well controlled with drop medication. The post-operative wound healing response remains the major barrier in surgical success. Scar tissue formation results in occlusion of the surgical drainage site created. As a consequence, the intraocular pressure rises once again. The current use of anti-scarring agents such as 5 Fluorouracil (5FU), is a well established method employed by ophthalmologists to clinically reduce the postoperative scarring response. However, in patients with a high risk of bleb failure, repeated subconjunctival injections of 5FU following bleb needling is often required resulting in increased clinical load and patient inconvenience. A slow release formulation of 5FU would be of benefit by releasing the 5FU into the subconjunctival space over an extended period thereby providing a prolonged therapeutic effect. In addition, hyaluronic acid is known to possess antifibrotic properties and from its gel-like physical state, would potentially act as a physical tissue spacer that may further limit active subconjunctival scarring at the site where it is injected. We hypothesise that injecting a mixture of 5FU with hyaluronic acid would give better outcomes than injecting 5FU alone. The aim of this study is to determine whether bleb needling with subconjunctival injection of Viscoelastic/5FU formulation is an effective method for prolonged drug delivery in preventing the post-operative scarring response. This will be a prospective case-controlled study involving patients who have already undergone trabeculectomy and who require bleb needling and subconjunctival 5FU injections.

NCT ID: NCT00607373 Completed - Clinical trials for Hypercholesterolemia

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

RADICHOL 1
Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy. This study consisted of a 26-week treatment period and a 24-week post-treatment follow-up period. Following treatment and Week 28 evaluations, participants could elect to enroll in an open-label extension study (301012-CS6; NCT00694109). Participants who were not eligible or elected not to enroll in the open-label extension study or who discontinued during the 28-week treatment period were followed in this study for 24 weeks from administration of the last dose of study drug.

NCT ID: NCT00605111 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Start date: December 2003
Phase: Phase 4
Study type: Interventional

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

NCT ID: NCT00604422 Completed - Ulcerative Colitis Clinical Trials

Evaluation of the PillCamâ„¢ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis

Start date: April 2007
Phase:
Study type: Observational

To evaluate the ability of the PillCam® Colon Capsule Endoscope to detect and classify Ulcerative colitis

NCT ID: NCT00600626 Completed - Clinical trials for Diabetes Mellitus, Type 2

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.

NCT ID: NCT00589238 Terminated - Breast Cancer Clinical Trials

Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery

Start date: January 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, doxorubicin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether combination chemotherapy is more effective with or without carboplatin in treating breast cancer. PURPOSE: This randomized phase II trial is studying giving paclitaxel together with doxorubicin and cyclophosphamide to see how well it works compared to giving paclitaxel together with doxorubicin, cyclophosphamide, and carboplatin in treating women with locally advanced breast cancer that can be removed by surgery.

NCT ID: NCT00589186 Active, not recruiting - Clinical trials for Head and Neck Cancer

Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

Start date: November 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer.

NCT ID: NCT00576823 Completed - Neurogenic Bladder Clinical Trials

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Alfahydro
Start date: December 2007
Phase: Phase 3
Study type: Interventional

Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure [LPP] of neuropathic etiology. Secondary objectives were: - To investigate the safety and tolerability of alfuzosin 0.2 mg/kg/day in children and adolescents, - To investigate the number of Urinary Tract Infection (UTI) episodes, - To investigate the pharmacokinetics of Alfuzosin (population kinetics).